RESEARCH MONOGRAPH · KDC-MN-280

Dutasteride

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 3 min read

Our opinion on this compound

76/100

Dual 5-AR inhibitor that hits both isoforms harder and longer, with proportionally more of everything that comes with that

Dutasteride is the next-generation 5-AR inhibitor that does what finasteride does, but more thoroughly and for longer. GlaxoSmithKline's compound inhibits both the type-I and type-II isoforms of 5-alpha-reductase with high potency, producing roughly 90-95% reduction in serum DHT versus the 65-70% reduction from finasteride. The half-life is also dramatically longer (about 5 weeks versus 6-8 hours for finasteride), which means the pharmacokinetic clearance after discontinuation is measured in months.

The mechanism story is straightforward. Both type-I and type-II 5-alpha-reductase are inhibited at low nanomolar concentrations, and the binding is essentially irreversible on relevant timescales. The dual inhibition matters mostly in tissues where type-I is the dominant isoform (skin, liver) and where the residual type-I activity in finasteride users leaves some DHT production untouched. The EPICS trial directly compared dutasteride and finasteride for BPH and showed modestly better symptom and volume reduction with dutasteride.

What we like is the depth of estrogen-suppression-via-DHT-reduction effects. Because more total DHT is suppressed and over a longer time course, dutasteride is a useful research tool for asking questions about what happens when 5-AR activity is essentially abolished rather than partially reduced. The CombAT trial provided substantial data on the combination of dutasteride and tamsulosin for BPH which shaped clinical practice in the 2010s.

What we dont like is essentially everything that makes dutasteride more aggressive than finasteride, just with longer kinetics. The post-finasteride syndrome literature has equivalent or arguably worse concerns for dutasteride given the longer drug exposure and more complete DHT suppression. The recovery profile after discontinuation is much slower because of the long half-life.

The breast cancer indication exploration in male populations (where DHT reduction shifts the androgen-to-estrogen ratio) is interesting basic endocrinology but hasnt translated to approved indications.

For research use dutasteride is the tool of choice when you want to study complete 5-AR inhibition. The dual isoform coverage matters for studies trying to dissociate DHT-mediated effects from other steroidogenic effects of androgens.

Sourcing is good. Available generically in most markets, the soft-gelatin capsule formulation is standard for the clinical product but research-grade powder is available with appropriate analytical verification.

Workhorse with the underappreciated angle being the much slower clearance and more profound DHT suppression versus finasteride. Useful research tool with proportionally larger risk profile.

Evidence: 80
Mechanism: 88
Reliability: 85
Safety: 55
Sourcing: 85
Value: 78
Signal: 70
Staying power: 70

Plain-language summary Intrigue 60 / 100

Dutasteride (Avodart) is the more aggressive cousin of finasteride, approved in 2002. It blocks both type I and type II 5-alpha-reductase (finasteride mainly hits type II), suppressing plasma DHT by 90 to 95 percent rather than 65 to 70 percent. That makes it more effective for prostate enlargement and, in head-to-head trials, slightly better for hair loss, but it also produces a higher rate of sexual side effects. The very long half-life (about five weeks) means the effect persists long after stopping. The post-finasteride-syndrome concern applies here too. Often used off-label for hair loss in patients who do not respond to finasteride. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Dual 5-alpha-reductase I/II inhibitor

A 4-azasteroid dual 5-alpha-reductase inhibitor (types I and II); more complete DHT suppression than finasteride.

Abstract

Dutasteride ((5-alpha,17-beta)-N-{2,5-bis(trifluoromethyl)phenyl}-3-oxo-4-azaandrost-1-ene-17-carboxamide; CAS 164656-23-9; molecular formula C27H30F6N2O2; molecular weight 528.53) is a 4-azasteroid dual 5-alpha-reductase inhibitor developed at GlaxoSmithKline and approved by the FDA in 2002 under the trade name Avodart. Distinct from finasteride by inhibition of both 5AR isozymes (type I Ki approximately 0.6 nM, type II Ki approximately 0.3 nM, both substantially more potent than finasteride at type II). Plasma DHT is reduced by approximately 90 to 95 percent at the 0.5 mg dose, compared to 65 to 70 percent for finasteride. Plasma half-life is approximately 5 weeks (the longest in the 5AR inhibitor class), reflecting tight tissue binding. Approved for benign prostatic hyperplasia; off-label use in androgenetic alopecia (often more effective than finasteride). The longer half-life means slower offset of effect on discontinuation but also slower washout for fertility planning. Sexual side effects parallel finasteride. Used as the canonical dual 5AR inhibitor in mechanism studies.

Mechanism of action

Dual 5-alpha-reductase type I and II inhibition; reduces plasma DHT by 90 to 95 percent. More complete DHT suppression than finasteride.

Reported research dose ranges

Clinical 0.5 mg in the published literature. Rodent studies 0.1 to 1 mg/kg.

References

Roehrborn CG, et al. The effects of dutasteride on prostate volume and DHT in men with BPH. Urology 2002.
Olsen EA, et al. The importance of dual 5-alpha-reductase inhibition in the treatment of male pattern hair loss. J Am Acad Dermatol 2006.
Bramson HN, et al. Unique preclinical characteristics of GG745, a dual 5-alpha-reductase inhibitor. J Pharmacol Exp Ther 1997.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-280

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Dutasteride

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs